Sector Funds

7 articles

Wall Street bets on technology and industrials to outpace the S&P 500

Wall Street analysts expect technology and industrials to deliver stronger gains than the S&P 500 through 2027, with sector ETFs like VGT and VIS offering focused access but also unique risks for investors seeking higher returns

View Story

Berkshire Hathaway CEO Greg Abel's Homebuilder Acquisition and the State Street SPDR S&P Homebuilders ETF

Berkshire Hathaway's $6.8 billion purchase of Taylor Morrison expands its homebuilding reach to 21 states, but the State Street SPDR S&P Homebuilders ETF has lagged the S&P 500 for nearly two decades-raising questions for investors seeking housing exposure

View Story

Sector ETFs Often Aren't as Diversified as They Seem

Many sector ETFs appear diversified but are heavily weighted toward just a few large companies, exposing investors to concentration risk that may not match their expectations for broad sector exposure

View Story

Portfolio Manager Shifts From Tech to Healthcare and Robotics ETFs

With tech and AI stocks dominating the S&P 500, a veteran manager is moving fresh capital into healthcare and robotics ETFs, aiming for long-term growth as sector leadership shows signs of rotation

View Story

VanEck Semiconductor ETF: A Decade of Exceptional Returns

The VanEck Semiconductor ETF has delivered a 1,930% total return over the past 10 years, far outpacing the S&P 500 and Nasdaq-100, but its concentrated sector exposure has also brought sharp volatility and multiple deep drawdowns

View Story

Vanguard Financials ETF vs Fidelity MSCI Financials Index ETF: A Comparison

Vanguard Financials ETF and Fidelity MSCI Financials Index ETF both offer broad access to U.S. financial stocks, but differ in asset size, expense ratio, and top holdings-key factors for investors weighing sector exposure

View Story

State Street Health Care Select Sector SPDR ETF vs. First Trust NYSE Arca Biotechnology Index Fund: A Comparison

Healthcare ETFs XLV and FBT offer sharply different approaches-one broad and low-cost, the other biotech-focused and higher risk. See how their fees, returns, volatility, and holdings stack up before choosing where to invest

View Story